OBP2B

Across TCGA pan-cancer cohorts, OBP2B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated OBP2B data layer compared with 20 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher OBP2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OBP2B expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

SARC, PRAD, and UCEC are the cancer types where OBP2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.162	0.767	.002	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	III,IV	1.000	0.470	.040	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

OBP2B–SARC (OS)

Open the SARC breakdown →